Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of "Hold" from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received an average "Hold" rating from 24 brokerages. Analysts have varied opinions, with some recommending sell, hold, or buy. The stock's target price averages $18.43. Recent insider trading and institutional investments have influenced stock ownership. The company reported better-than-expected quarterly earnings, with revenue up 51.6% year-over-year. Intellia focuses on genome editing therapeutics, with several programs in clinical trials.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has earned an average rating of "Hold" from the twenty-four brokerages that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $18.4348.

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

A number of equities research analysts have issued reports on the stock. Chardan Capital cut their price objective on shares of Intellia Therapeutics from $48.00 to $26.00 and set a "buy" rating for the company in a report on Friday, November 7th. HC Wainwright cut their target price on shares of Intellia Therapeutics from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, November 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. William Blair downgraded shares of Intellia Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, October 27th. Finally, Wells Fargo & Company reduced their target price on Intellia Therapeutics from $17.00 to $12.00 and set an "equal weight" rating on the stock in a report on Friday, November 7th.

Get Intellia Therapeutics alerts:

Get Our Latest Research Report on NTLA

Insiders Place Their Bets

Analysts Think These Stocks Could More Than Double in Value

In related news, CAO Michael P. Dube sold 1,871 shares of the company's stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the sale, the chief accounting officer owned 55,266 shares of the company's stock, valued at $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 3.10% of the company's stock.

Institutional Trading of Intellia Therapeutics

Large investors have recently made changes to their positions in the business. Contrarius Group Holdings Ltd lifted its holdings in shares of Intellia Therapeutics by 279.4% in the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company's stock valued at $101,719,000 after acquiring an additional 4,337,428 shares during the last quarter. Jupiter Asset Management Ltd. bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at approximately $23,519,000. Marex Group plc purchased a new position in shares of Intellia Therapeutics in the 2nd quarter worth approximately $5,849,000. Farallon Capital Management LLC bought a new position in shares of Intellia Therapeutics during the 3rd quarter valued at approximately $10,486,000. Finally, Vanguard Group Inc. increased its position in shares of Intellia Therapeutics by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock valued at $76,447,000 after purchasing an additional 561,978 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Performance

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Shares of NTLA stock opened at $8.55 on Wednesday. The stock has a fifty day simple moving average of $16.49 and a two-hundred day simple moving average of $12.58. The firm has a market capitalization of $990.35 million, a PE ratio of -2.00 and a beta of 2.44. Intellia Therapeutics has a 52-week low of $5.90 and a 52-week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.12 million. During the same quarter in the prior year, the company posted ($1.34) earnings per share. The business's quarterly revenue was up 51.6% compared to the same quarter last year. On average, sell-side analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Should You Invest $1,000 in Intellia Therapeutics Right Now?

Before you consider Intellia Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.

While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here